Interferon-alfa in the management of cystic craniopharyngioma in children under 5 years of age
Keywords:neurosurgery, pharmacological treatment, chemotherapy, brain tumors
Introduction: the best therapeutic option for the management of craniopharyngioma in younger children remains controversial, ranging from complete surgical resection, partial surgical resection associated with radiotherapy and application of chemotherapeutic agents such as bleomycin and interferon-alfa.
Objective: to verify the response to treatment with interferon-alfa via Ommaya reservoir in a group of children under 5 years of age with diagnosis of cystic craniopharyngioma.
Methods: description of a case series through consecutive review of medical records of children under 5 years of age diagnosed with cystic adamantinomatous craniopharyngioma who had an Ommaya reservoir catheter surgically implanted for intratumoral application of interferon-?.
Results: seven children aged 18 to 60 months (median 46 months) with the abovementioned diagnosis and treated with interferon-alfa between 2010 and 2019, according to a pre-established protocol, were identified. A reduction in tumor volume, ranging from 88 to 100%, one year after the end of treatment was observed in the study sample. There were no complications that justified the interruption or modification of the established therapy.
Conclusion: in all the cases evaluated of children less than 5 years of age with predominantly cystic adamantinomatous craniopharyngioma we observed a reduction of tumor volume on magnetic resonance imaging one year after the end of treatment with interferon-alfa.
How to Cite
Copyright (c) 2021 Jose Roberto Tude Melo, Felipe Reynan Paiva Vieira Santos, Igor Campos da Silva, José Henrique Silva Barreto
This work is licensed under a Creative Commons Attribution 4.0 International License.
When publishing in Archives of Pediatric Neurosurgery journal, authors retain the copyright of their article and agree to license their work using a Creative Commons Attribution 4.0 International Public License (CC BY 4.0), thereby accepting the terms and conditions of this license (https://creativecommons.org/licenses/by/4.0/legalcode).
The CC BY 4.0 license terms applies to both readers and the publisher and allows them to: share (copy and redistribute in any medium or format) and adapt (remix, transform, and build upon) the article for any purpose, even commercially, provided that appropriate credit is given to the authors and the journal in which the article was published.
Authors grant Archives of Pediatric Neurosurgery the right to first publish the article and identify itself as the original publisher. Under the terms of the CC BY 4.0 license, authors allow the journal to distribute the article in third party databases, as long as its original authors and citation details are identified.